Windlas Biotech · Material risks, their source context, and severity in the latest available quarter.
ConCallIQ research layer
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Q3 Trade Generics growth slowed to 7% YoY versus 18% for 9M FY26 and historical quarters of up to 74%. Management attributed this to competitive intensity from new entrants, institutional order lumpiness, and execution factors. Peers with 2.5x the base are growing faster.
Management admitted injectable capacity utilization has been lower than expectations but declined to disclose specific numbers citing competitive sensitivity. No clear timeline provided to reach 70-80% utilization target.
An analyst directly asked for 9-month net cash generation which management deflected, stating balance sheet is only limited reviewed and they want to refrain from sharing. This limits visibility into working capital efficiency and leverage.
Over 95% of sales are domestic India. Any policy changes (NLEM pricing, PLI scheme changes), regulatory shifts, or industry volume growth data gaps (government program purchases not captured by IQVIA/Awaz) could impact revenue visibility.
